About

About Ever Supreme Bio Technology About Ever Supreme Bio Technology Co., LTD Ever Supreme is a leading company in the field of research and innovation, specializing in immune cell therapy and stem cell new drug development in Taiwan. While current CAR-T therapies are limited to hematologic malignancies and autologous treatments, Ever Supreme's new generation CAR001 therapy offers an off-the-shelf solution that utilizes BiTE-secreting CAR-γδT as a dual targeting strategy for the treatment of solid tumors. Recently, Ever Supreme's research on CAR.BiTE-γδT immune cell therapy for pre-clinical animal studies was published in the prestigious journal "Advanced Science." In addition, the US FDA and Taiwan FDA approved Phase I/IIa clinical trial and our clinicaltrial.gov ID # is NCT06150885. Afterwards, we have started to enroll patient. ver Supreme Bio Technology Co., Ltd. is a clinical-stage regenerative medicine company developing next-generation allogeneic cell therapies, including the innovative mRNA CAR-gamma delta T cell therapy (CAR001) for refractory and relapsed solid tumors, currently in a Phase I/IIa clinical trial. To date, CAR001 has been administered to 10 subjects and showed promising preliminary efficacy without any significant safety concerns. In addition to CAR001, Ever Supreme is advancing novel therapeutics including Exosome-Based In Vivo CAR-T (EXO001), Nanocapsules Drug Delivery (INSP03), and Exosome-Based Therapies for Neurodegenerative disease (dEV-001). With research and manufacturing capabilities based in Taiwan, we are dedicated to translating innovative concepts into safe, scalable, and effective treatments. Our corporate strategy focuses on technology licensing, strategic partnerships, and global expansion, aiming to accelerate the progression from early-stage R&D to successful worldwide commercialization.